Tower View Wealth Management’s Palvella Therapeutics PVLA Stock Holding History

Tower View Wealth Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	–	–	192
2023 Q3	$0	Hold	13	–	–	﹤0.01%	194
2023 Q2	$0	Hold	13	–	–	﹤0.01%	195
2023 Q1	$1K	Hold	13	–	–	﹤0.01%	152
2022 Q4	$1K	Hold	13	–	–	﹤0.01%	160
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	163
2022 Q2	$2K	Buy	+13	New	+$2.37K	﹤0.01%	151

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

1IA

1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Tower View Wealth Management's PVLA Position: Q4 2023 in Review

Tower View Wealth Management sold out of Palvella Therapeutics (PVLA) in Q4 2023, closing a stake of 13 shares.

Tower View Wealth Management first reported a position in PVLA in Q2 2022 and held it in 6 quarters. The position peaked at $2K in Q2 2022. 46 funds tracked by Wall St. Rank hold PVLA as of Q4 2023.

Tower View Wealth Management reported no remaining Palvella Therapeutics position as of Q4 2023 after selling out during the quarter.
Tower View Wealth Management sold 13 Palvella Therapeutics shares in Q4 2023.
Tower View Wealth Management first reported a position in Palvella Therapeutics in Q2 2022 and held it in 6 quarters.
Tower View Wealth Management's Palvella Therapeutics position peaked at $2K in Q2 2022.
46 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2023.

Based on Tower View Wealth Management's 13F filing for Q4 2023, filed 6 Feb 2024.